MLN2238

Cat. # SI9725

Background: MLN2238 is a proteasome inhibitor also known as ixazomib. MLN2238 is the biologically active form of MLN9708.[1] Under physiological conditions, the MLN9708 boronic citrate ester is rapidly hydrolyzed to a boronic acid. Much like Bortezomib, MLN2238 reversibly inhibits the trypsin- and chymotrypsin-like activities of the proteasome.[2]

Application: *In vitro* and cellular studies of proteasome function.

Product Information:

CAS No.	1072833-77-2
Purity:	>99.0% by HPLC
Molecular Weight:	361.03 Da
Physical State:	Powder
Quantity:	5 mg
Solubility:	DMSO (72 mg/mL); ethanol (9 mg/mL); Water (<1 mg/mL)
Storage:	Store desiccated as supplied at -20ºC for 2 years.



Formula: $C_{14}H_{19}BCl_2N_2O_4$

References

1. Kupperman, E., Lee, E.C. et al. (2010). "Evaluation of the proteasome inhibitor MLN9708 in preclinical models of human cancer." Cancer Res **70**(5): 1970-1980.

2. Schrader, J., Hennenberg, F., et al. (2016). "The inhibition mechanism of human 20S proteasomes enables next-generation inhibitor design." Science **353**(6299): 594-598.